2008 Press Releases
TSX:V - IXS
NASD OTC:BB: IXSBF
May 8, 2008
InNexus Biotechnology Hosts Inaugural Event of U.S. Department of Commerce -- To Highlight Foreign Direct Investment in USA with Invest in America Program --
BRITISH COLUMBIA, Canada- 8 May 2008-InNexus Biotechnology Inc. (OTCBB: IXSBF)(TSX VENTURE: IXS), (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies, yesterday hosted the U.S. Department of Commerce Invest in America event sponsored by the Greater Phoenix Economic Council at InNexus’ facilities located on the Campus of Mayo Clinic in Scottsdale, Arizona. The event highlighted the importance of Foreign Direct Investment (FDI) for jobs and economic growth through a series of site visits to foreign investor-owned facilities in States across the USA.
“I’m very happy with the company’s investment in Arizona,” said Jeff Morhet Chairman and CEO of InNexus. “We plan to expand beyond our current team, as Arizona has offered us what is needed, including a skilled work force. There are greater resources available to technology companies in Arizona than most people give it credit for.”
*To view pictures and news coverage of the event, go to http://www.ixsbio.com/trade_event_050608.html.
Barry Broome, President of the Greater Phoenix Economic Council said, “Right now, this is an unprecedented opportunity for us to engage in international markets, through the value of the dollar. We welcome InNexus and others as they represent superior opportunities and companies that we endeavor to see investing in Arizona.”
About Invest in America
The Department of Commerce launched Invest in America last year. It is the first federal-level U.S. investment promotion effort in a generation. Invest in America coordinates across U.S. Government agencies to promote inward investment and address federal issues that may impede investment. Through Invest in America, the Department of Commerce promotes the United States as the best place in the world to do business and reinforces the unequivocal and long-standing commitment by the United States to open investment policies. Invest in America is facilitating Invest in America Week activities and all 50 states are participating.
About InNexus
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL™ technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.
Contact:
Jeff Morhet, Chairman & Chief Executive Officer
Dr. Thomas Kindt, Chief Scientific Officer
InNexus Biotechnology Inc.
480-862-7500
www.ixsbio.com
